Keryx Biopharmaceuticals Inc. (KERX)

3.36
0.07 2.04
Prev Close 3.43
Open 3.44
Day Low/High 2.96 / 3.46
52 Wk Low/High 2.47 / 5.98
Volume 2.56M
Avg Volume 1.12M
Exchange
Shares Outstanding 120.38M
Market Cap 404.46M
EPS -1.40
Div & Yield N.A. (N.A)

Latest News

Lifshitz & Miller LLP Announces Investigation Of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., And Sonic Corp.

Lifshitz & Miller LLP Announces Investigation Of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., And Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX

NEW YORK, Oct. 1, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Keryx Biopharmaceuticals, Inc.

Wolf Popper LLP Investigates The Proposed Acquisition Of Keryx Biopharmaceuticals, Inc. By Akebia Therapeutics, Inc.

Wolf Popper LLP Investigates The Proposed Acquisition Of Keryx Biopharmaceuticals, Inc. By Akebia Therapeutics, Inc.

NEW YORK, July 23, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Keryx Biopharmaceuticals, Inc.

WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.

WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.

NEW YORK, June 29, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc.

Oversold Conditions For Keryx Biopharmaceuticals (KERX)

Oversold Conditions For Keryx Biopharmaceuticals (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of KERX December 21st Options Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the December 21st expiration.

First Week of April 20th Options Trading For Keryx Biopharmaceuticals (KERX)

First Week of April 20th Options Trading For Keryx Biopharmaceuticals (KERX)

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the April 20th expiration.

Commit To Buy Keryx Biopharmaceuticals At $3, Earn 17.9% Annualized Using Options

Commit To Buy Keryx Biopharmaceuticals At $3, Earn 17.9% Annualized Using Options

Investors eyeing a purchase of Keryx Biopharmaceuticals Inc. shares, but cautious about paying the going market price of $4.42/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

KERX January 2020 Options Begin Trading

KERX January 2020 Options Begin Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2020 expiration.

Interesting KERX Put And Call Options For June 2018

Interesting KERX Put And Call Options For June 2018

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading this week, for the June 2018 expiration.

Keryx Biopharmaceuticals Becomes Oversold (KERX)

Keryx Biopharmaceuticals Becomes Oversold (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D- (Sell)